Infectious Diseases - Global Clinical Trial Landscape (2025)

The global infectious disease clinical trial landscape has rapidly expanded between 2020 and 2024, driven by the urgency of emerging threats, technological innovation, and evolving regulatory frameworks. Innovations in mRNA technology, AI-driven drug discovery, platform trial designs, and decentralized clinical trials have accelerated development timelines and broadened access. However, challenges remain, especially in low- and middle-income countries, where underrepresentation, fragmented regulation, and limited funding hinder progress. Strategic solutions include regulatory harmonization, public-private partnerships, and regionally tailored clinical infrastructure. This evolving landscape underscores the critical need for sustained investment, global collaboration, and data-driven approaches to accelerate therapeutic breakthroughs and improve global health security.